A Phase III trial of a quadrivalent meningococcal ACWY‑TT conjugate vaccine in infants aged 6 to 23 months conducted in the U.S. and Puerto Rico demonstrated favorable immunogenicity and safety, supporting broader pediatric use. The multicenter study met prespecified endpoints for serogroup coverage and tolerability. Investigators reported robust antibody responses across targeted serogroups with an acceptable reactogenicity profile in the toddler population. The data aim to inform immunization schedules and regulatory submissions for infant and toddler licensing. Pediatricians and public‑health programs evaluating meningococcal prevention now have updated clinical evidence for early‑life immunization strategies. Manufacturers may position the vaccine to address gaps in serogroup coverage for young children.